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Table.
Aortic diameter
size, cm N = 227
Screening
AAA size, cm
Follow-up
AAA size, cm
Average
follow-up, years
Percent follow-up
>6 months
Expansion
rate, cm/yr
3.0-3.9 157 3.4 3.7 2.1 157/362 (43.4%) 0.16
4.0-5.4 70 4.5 4.9 1.8 70/113 (61.9%) 0.22
P value - - - - 0.04 0.71
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562 Abstracts August 2013of 3.0-5.4 cm were identiﬁed. The purpose of our study is to investigate the
fate of patients diagnosed with an aorta too small for repair.
Methods: Data were extracted through a regional Veterans Affairs
Service Network to identify all veteran males 65-75 years of age who
smoked greater than 100 cigarettes during their lifetime. Patients meeting
screening criteria were evaluated for an AAA as part of the patient's health
maintenance. An aortic diameter of 3.0 cm to 3.9 cm was considered to be
a SMALL AAA, whereas INTERMEDIATE AAA was an aortic diameter
4.0-5.4 cm. Follow-up rates, rate of aortic expansion, and risk factors for
expansion were evaluated. Chi squared analysis and two-tailed t-test were
used to compare groups. A P-value < .05 was considered signiﬁcant.
Results: A total of 9,751 patients (71.5 6 5.6 SD years of age) were
screened for an AAA over a 5 year period from January 1, 2007 to
December 31, 2011. A total of 698 patients were identiﬁed with an aneu-
rysm (7.1%). Five-hundred-nineteen patients had an aortic diameter of
3.0-5.4 cm upon initial screening; 13 aneurysms were repaired and 31
had follow-up imaging less than 6 months after initial screening. During
study period, 47.8% (227/475) patients had a follow-up image study
completed more than 6 months after initial screening. The average expan-
sion rate for SMALL AAA was 0.16 cm/year versus INTERMEDIATE
AAA with 0.22 cm/year (P < .71). No signiﬁcant differences were found
in risk factors between groups.
Conclusions: The long-term implementation of an AAA screening
effort has led to the diagnosis of a signiﬁcant number of patients with small
and intermediate diameter aortas with lacking data-driven recommendations
for long term follow-up. Our data suggest that follow-up among patients
with small to intermediate sized aneurysm are substantially low. Expansion
rates are variable and risk for expansion need to be further elucidated.Endoleaks Following EVAR: Long-Term Outcome and Clinical
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Objectives: EVAR is considered the standard therapy for most
patients with AAA. Endoleak is a well-known EVAR-related complication
that requires long-term follow-up. However, patient follow-up is often chal-
lenging outside clinical trials. We sought to evaluate the incidence and the
effect of endoleaks in a VA health care system where long-term follow-up is
ensured.
Methods: We retrospectively evaluated 213 consecutive patients who
received EVARs at a referral VA medical center. Age, aneurysm size, patency
of lumbar and IMA, and follow-up evaluations were recorded. Type of
endoleak, date of detection and intervention were also documented.
Patients who had less than 1-year follow-up were excluded. Student’s
t-test and spearman correlation were used for data analysis.
Results: A total of 180 patients were included in the analysis with
a mean follow-up of 51 months. Thirty-ﬁve were excluded due to death
within 1 year of EVAR (n ¼ 14), lost to follow-up (n ¼ 5), or too early
for 1 year CT (n ¼ 14). Fifty-two (28.9%) patients had endoleaks. The
mean diagnosis time for type I (n¼12) and type III (n ¼ 4) endoleaks
was 46 and 21 months post-EVAR and the majority (62.5%) were diag-
nosed >1 year following EVAR. All type I and III endoleaks received
secondary interventions except one who presented with aneurysm rupture.
Type II endoleak was detected in 37 patients on an average of 14 months
following EVAR and 39.4% of which were detected >1 year post EVAR.
Patients without documented endoleak had signiﬁcant decrease in aneurysm
size compared to the preoperative size (4.78 vs 5.65 cm; P < .001), while
those with type II endoleak had increase compared to the preop (5.82 vs
5.66 cm). Importantly, 51.4% of the patients with a type II endoleak had
signiﬁcant AAA enlargement (0.75 cm). No signiﬁcant correlation between
the size of IMA or lumbar to AAA enlargement among the patients with
a type II endoleak was seen. 9 patients with type II endoleak received
secondary interventions.Conclusions: We demonstrated that endoleak often appears long
after EVAR despite the normal initial imaging and that type II endoleak
is frequently associated with long-term aneurysm enlargement requiring
reinterventions. This study underscores that type II endoleak is not benign
as previously thought and that vigilant long-term surveillance following
EVAR is critical.
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Objectives: Patients receiving inter-facility transfer to a higher level of
medical care for ruptured abdominal aortic aneurysms (rAAA) are an impor-
tant minority that are not well characterized and typically omitted from
outcomes and quality indicator studies. Our objective was to compare
patients transferred for treatment of rAAA with those treated without trans-
fer, with particular emphasis on quality of care.
Methods: We linked longitudinal data from 2005-2010 HCUP State
Inpatient Databases and Emergency Department Databases from Califor-
nia, Florida, and New York. Patients were identiﬁed using ICD-9-CM
codes. Our main outcome variables were mortality, length of stay (LOS),
and cost. Data included discharge information on both the transfer-out
and transfer-in hospital. We used univariate and multivariate analysis to
identify variables independently associated with transfer and in-hospital
mortality.
Results: Of 4413 rAAA patients identiﬁed with intent to treat, 819
(18.6%) were transferred prior to receiving deﬁnitive care. Of those trans-
ferred, 134 (16%) died without undergoing AAA repair. Risk-adjusted in-
hospital mortality did not differ by transfer status (45.7% vs 43.1%; P ¼ .2),
but LOS (median, 10 vs 9 days; P ¼ .008), and hospital costs ($158,000 vs
$146,000; P ¼ .04) were higher for those transferred. By multivariate anal-
ysis, age (OR, 0.98; 95% CI, 0.97-0.99; P< .001) private insurance vs Medi-
care (OR, 0.59; 95% CI, 0.46 - 0.77; P< .001), and comorbidity (OR, 0.93;
95% CI, 0.89-0.97; P ¼ .003) were negatively associated with transfer.
Weekend presentation (OR, 1.28; 95% CI, 1.08-1.52; P ¼ .005) was posi-
tively associated with transfer.
Conclusions: Mortality was similar for patients transferred for rAAA
repair compared with those not transferred, although 16% of transferred
patients died without receiving deﬁnitive repair. Transferred patients used
signiﬁcantly more hospital resources. Improving systems and guidelines
for inter-facility transfer may improve the quality of care received by these
patients and decrease associated hospital resource utilization.
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Objectives: To analyze the early and late outcomes of patients who
require a suprarenal aortic cross-clamp during elective open repair of an
abdominal aortic aneurysm (AAA).
Methods: Patients from 1998-2011 who required a suprarenal aortic
cross-clamp during elective open AAA repair were reviewed. Data abstracted
included: demographics, comorbidities, preoperative, perioperative, and late
renal function; late interventions related to AAA repair; and late mortality. A
decrease in renal function was deﬁned as a >30% decline in eGFR as
compared to the preoperative value. Primary outcomes included renal func-
tion, intervention free survival and overall survival.
Results: One hundred eighty-six patients underwent open AAA
repair; 63 of whom required a suprarenal cross-clamp. Mean age was 72
with 81% being male. Mean preoperative creatinine was 1.2 mg/dL and
mean preoperative eGFR was 65 mL/min/1.73m2. Location of the aortic
cross-clamp was suprarenal (36), supramesenteric (18), and supraceliac (9).
Perioperatively, 15 (24%) patients experienced a signiﬁcant decrease in
